Sage Journals: Discover world-class research

Abstract

Background

Extracellular matrix-degrading proteinases are upregulated in atherosclerotic lesions and can contribute to subsequent pathological events. In the present nested case–control study, we investigated the association of serum concentrations of matrix metalloproteinases MMP-7, MMP-8, and MMP-13, tissue inhibitor of metalloproteinase-1 (TIMP-1), and neutrophil elastase (NE) with incident cardiovascular disease (CVD) events.

Design

The FINRISK97 cohort included 8090 persons with no history of CVD. During the 10-year follow up, 471 incident CVD cases were ascertained and for them, three individually matched controls (n = 1413) were selected. The CVD events included myocardial infarction, stroke, coronary revascularization, and CVD death.

Results

Compared to the controls, the cases had significantly higher serum mean concentrations of MMP-7, MMP-8, and TIMP-1, as well as MMP-7/TIMP-1 ratio. In multivariate analyses adjusted for CVD risk factors, MMP-7, MMP-8, TIMP-1, and MMP-8/TIMP-1 ratio were associated with the risk for incident CVD: OR 1.16 (95% CI 1.03–1.31), OR 1.13 (95% CI 1.01–1.26), OR 1.16 (95% CI 1.02–1.31), and OR 1.13 (95% CI 1.00–1.27) respectively, per SD-increase of log-transformed unit. The associations, however, attenuated into non-significant after adjusting for C-reactive protein (CRP) concentrations.

Conclusions

MMP-7 and MMP-8, which are upregulated during inflammation, can form a proinflammatory tissue destructive cascade. They can be regarded as risk factors, and thus as potential biomarkers for incident CVD. The balance between these MMPs and their tissue inhibitor may indicate vulnerability to plaque rupture.

Keywords

Biomarkers cardiovascular diseases epidemiology inflammation matrix metalloproteinases

Get full access to this article

View all access options for this article.

References

Sorsa

Tjäderhane

Konttinen

. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38: 306–321.

Bäck

Ketelhuth

Agewall

. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410–428.

Galis

Sukhova

Lark

. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493–2503.

Inokubo

Hanada

Ishizaka

. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211–217.

Lubos

Schnabel

Rupprecht

. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006; 27: 150–156.

Frantz

Störk

Michels

. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008; 10: 388–395.

Pussinen

Sarna

Puolakkainen

. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol 2012. doi:10.1016/j.ijcard.2011.12.095.

Burke

. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology 2004; 209: 51–56.

Halpert

Sires

Roby

. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93: 9748–9753.

10.

Lindstedt

Saarinen

Kalkkinen

. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem 1999; 274: 22627–22634.

11.

Wilson

Anderton

Schwalbe

. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 2006; 113: 438–445.

12.

Herman

Sukhova

Libby

. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104: 1899–1904.

13.

Turu

Krupinski

Catena

. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006; 187: 161–169.

14.

Laxton

Duchene

. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 2009; 105: 921–929.

15.

Tuomainen

Nyyssönen

Laukkanen

. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007; 27: 2722–2728.

16.

Sukhova

Schönbeck

Rabkin

. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503–2509.

17.

Dollery

Owen

Sukhova

. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107: 2829–2836.

18.

Leclercq

Houard

Philippe

. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420–1429.

19.

Cohen

Keegan

Sarfati

. Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients with abdominal aortic aneurysms. J Invest Surg 1991; 4: 423–430.

20.

Hughes

Saarela

Blankenberg

. A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. Eur J Prev Cardiol 2012; 19: 874–884.

21.

Pajunen

Koukkunen

Ketonen

. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132–137.

22.

Vartiainen

Laatikainen

Peltonen

. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39: 504–518.

23.

Salomaa

Havulinna

Saarela

. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 2010; 5: e10100–e10100.

24.

Dozier

Escobar

Lindsey

. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP13. Med Chem 2006; 2: 523–526.

25.

Cavusoglu

Ruwende

Chopra

. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101.e1–1101.e8.

26.

Pradhan-Palikhe

Vikatmaa

Lajunen

. Elevated MMP-8 and decreased myeloperoxidase concentrations associate significantly with the risk for peripheral atherosclerosis disease and abdominal aortic aneurysm. Scand J Immunol 2010; 72: 150–157.

27.

Kato

Momiyama

Ohmori

. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005; 69: 1035–1040.

28.

Weiss

. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365–376.

29.

Henriksen

Sallenave

. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol 2008; 40: 1095–1100.

30.

Hansson

Robertson

Söderberg-Nauclér

. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297–329.

31.

Sorsa

Tervahartiala

Leppilahti

. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res 2011; 63: 108–113.

Serum tissue-degrading proteinases and incident cardiovascular disease events

Abstract

Background

Design

Results

Conclusions

Keywords

Get full access to this article

References